Quick Answer
Syndax Pharmaceuticals Inc reported Stockholders Equity of $64.63 million for fiscal year 2025.
Syndax Pharmaceuticals Inc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $64.63M | -77.6% |
| 2024 | $288.12M | -48.0% |
| 2023 | $554.20M | +18.6% |
| 2022 | $467.45M | +14.5% |
| 2021 | $408.37M | +61.9% |
| 2020 | $252.19M | +698.1% |
| 2019 | $31.60M | -40.4% |
| 2018 | $53.05M | -49.1% |
| 2017 | $104.32M | +24.0% |
| 2016 | $84.14M | +133.3% |
| 2015 | -$252.41M | -65.4% |
| 2014 | -$152.57M | -18.8% |
| 2013 | -$128.47M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $115.43M | -68.5% | -26.7% |
| June 30, 2025 | $157.42M | -63.8% | -26.8% |
| March 31, 2025 | $215.06M | -56.3% | -25.4% |
| December 31, 2024 | $288.12M | -48.0% | -21.4% |
| September 30, 2024 | $366.43M | +2.0% | -15.6% |
| June 30, 2024 | $434.34M | +8.6% | -11.7% |
| March 31, 2024 | $491.89M | +12.9% | -11.2% |
| December 31, 2023 | $554.20M | +18.6% | +54.3% |
- Syndax Pharmaceuticals Inc showed a decrease of -77.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, Syndax Pharmaceuticals Inc’s stockholders equity has grown by 150.3% (from -$128.47 million to $64.63 million).
- The most recent figure is from Syndax Pharmaceuticals Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: